Enterprise Value
3.231B
Cash
565.7M
Avg Qtr Burn
-106.6M
Short % of Float
14.44%
Insider Ownership
0.89%
Institutional Own.
-
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Omecamtiv Mecarbil (cardiac myosin activator) Details Pancreatic cancer, Heart disease, Heart failure | NDA FDA meeting | |
Aficamten (CK-274) (cardiac myosin inhibitor) Details Heart disease, Hypertrophic cardiomyopathies Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
CK-4021586 (CK-586) (cardiac myosin inhibitor) Details Heart disease, Heart failure | Phase 1 Data readout | |
CK-3828136(CK-136)(cardiac troponin activator) Details Heart disease, Heart failure, Epilepsy | Phase 1 Data readout | |
Reldesemtiv (CK-601) (next-generation fast skeletal muscle troponin activator (FSTA)) Details Amyotrophic lateral sclerosis, Neurodegenerative disease | Failed Discontinued |